Corneal endothelial cell loss and intraocular pressure following phacoemulsification using a new viscous-cohesive ophthalmic viscosurgical device.

PURPOSE: To compare results of two ophthalmic viscosurgical devices (OVDs)-Viscoat (a dispersive OVD, Alcon) and FR-Pro (a viscous-cohesive OVD, Rayner), in phacoemulsification surgery. METHODS: A prospective randomized controlled study. Patients undergoing phacoemulsification were randomly assigned to receive one of the two OVDs. Exclusion criteria were age under 40, preoperative endothelial cell count (ECC) below 1,500 cells/mm2 and an eventful surgery. The primary outcome was change in ECC from baseline to postoperative month one and month three. Secondary outcomes were the difference between ECC at postoperative month one and month three, changes in IOP and occurrence of an IOP spike ≥ 30 mmHg after surgery. RESULTS: The study included 84 eyes-43 in the Viscoat group and 41 in the FR-Pro group. Mean cell density loss at month one and month three was 17.0 and 19.2%, respectively, for the Viscoat group and 18.4 and 18.8%, respectively, for the FR-Pro group, with no statistically significant difference between the groups (p = 0.772 and p = 0.671, respectively). The mean ECC difference between the month one and month three visits was 50.5 cells/mm2 and was not statistically significant (p = 0.285). One eye in each group had an IOP spike ≥ 30 mmHg, both normalized by postoperative week one. CONCLUSIONS: Viscoat and FR-Pro have comparable results following phacoemulsification surgery, suggesting that while FR-Pro is not a dispersive OVD, its endothelial cell protection may be comparable to one, perhaps due to the addition of sorbitol. Furthermore, a one-month follow-up of ECC seems sufficient in such trials.

Central retinal vein occlusion in a young healthy COVID-19 patient: A case report.

PURPOSE: We detail a unique case of a healthy 33-year-old suspected COVID-19 patient who presented with unilateral Central Retinal Vein Occlusion, possibly as a complication of COVID-19. OBSERVATIONS: A 33-year-old healthy male was referred to the emergency department due to blurred vision in his left eye for the past month, accompanied by flashes of light without any accompanying neurological symptoms. The patient reported a three-week period of fatigue, dry cough, and shortness of breath ended about 2 weeks prior to the ocular symptoms. He was not tested for COVID-19 at the time of his respiratory complaints.The clinical examination and the ancillary tests confirmed the diagnosis of a left eye Central Retinal Vein Occlusion.During admission, a real-time reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2 from a nasopharyngeal swab was performed and was found to be negative, however, an IgG/IgM Rapid Test (Inzek International Trading, the Netherlands) was performed and was found to be IgM negative and IgG Positive for SARS-CoV-2, confirming recovery from COVID-19. CONCLUSIONS AND IMPORTANCE: To the best of our knowledge this is the first report of CRVO in association with COVID-19.As the literature on human ocular manifestations of COVID-19 is still sparse, our case emphasizes the need for further investigation of ocular complication associated with this novel disease.

The accuracy of the double-K adjustment for third-generation intraocular lens calculation formulas in previous keratorefractive surgery eyes.

PURPOSE: To evaluate the effect of the double-K (DK) modification on third-generation formulas. METHODS: Thirty-eight previously myopic and 24 previously hyperopic eyes that underwent phacoemulsification with intraocular lens (IOL) insertion after Laser in situ keratomileusis (LASIK) were evaluated. Pre-LASIK refraction and keratometry, post-LASIK topography, axial length (AL), IOL type and power, and 1-month postphacoemulsification refraction were recorded spherical equivalent after phacoemulsification (SE(postphaco)). Measured corneal power was adjusted using published and validated methods for postmyopic and posthyperopic LASIK. For each eye, and using SE(postphaco), different DK-IOL formulas were used to calculate the corresponding IOL power, the outcome measure, which was compared with the implanted IOL. RESULTS: DK-Holladay 1 yielded the highest Pearson correlation coefficient (PCC), 0.955 for myopes and 0.943 for high myopes (AL>26 mm). Mean error (ME) and mean absolute error (MAE) for myopes for DK Sanders-Retzlaff-Kraff theoretical formula [DK-SRK/T] were 0.44±0.84 D and 0.75±0.61 D for DK-SRK/T compared with -0.04±0.67 D and 0.52±0.40 D for DK-Holladay 1 (P<0.001 and P=0.016, respectively), and 0.03±0.88 and 0.64±0.58 for DK-Hoffer Q. For high myopes, ME and MAE were 0.75±0.81 D and 0.84±0.69 D for DK-SRK/T, and -0.05±0.74 D (P<0.0001) and 0.57±0.45 D (P=0.019) for DK-Holladay 1. About 29% of DK-SRK/T eyes with large AL had MAE>1.5 D, compared with 0% for DK-Holladay 1 and 14% for DK-Hoffer-Q. Eyes with previous hyperopic LASIK faired similarly for all formulas, with similar PCCs, and only 8% in each category with MAE>1.5 D. CONCLUSIONS: DK-SRK/T overestimates IOL power in eyes with large AL, especially with concomitant steep pre-lasik keratometry. Among third-generation formulas, DK-Holladay 1 seems more accurate to use in postmyopic LASIK eyes.

Staphylolysin is an effective therapeutic agent for Staphylococcus aureus experimental keratitis.

BACKGROUND: Therapy of S. aureus keratitis is increasingly challenging due to emerging resistant strains. Staphylolysin (LasA protease) is a staphylolytic endopeptidase secreted by Pseudomonas aeruginosa. The purpose of the current study was to study the effect of treatment with staphylolysin on experimental keratitis caused by various Staphylococcus aureus strains. METHODS: The therapeutic effect was studied in a keratitis model induced in rabbits by intrastromal injections of 10(3) S. aureus cells of three different methicillin-resistant S. aureus (MRSA) strains and one methicillin-susceptible S. aureus strain (MSSA). Topical treatment with either staphylolysin or bovine serum albumin (BSA; control) was applied every half hour for 5 h, starting at 4 h after infection. Corneas were removed for bacterial quantification. Histopathological analysis was performed on MSSA-infected rabbits, killed at either one or 84 h after completion of treatment and on uninfected eyes 1 h after treatment termination. RESULTS: The number of bacteria in the staphylolysin-treated corneas was significantly reduced in all infections with the four S. aureus strains studied as compared to controls: the staphylolysin-treated eyes infected with MRSA strains were either completely sterilized or showed a 3-4 orders of magnitude decrease in the number of cfu/cornea (p = 0.004 to 0.005); all of the staphylolysin-treated MSSA-infected eyes were sterile. Histopathological analysis of the methicillin-sensitive (MSSA) strain-infected eyes at 84 h after completion of treatment showed moderate inflammation in the staphylolysin-treated eyes as compared with extensive abscess formation in the control group. The uninfected corneas showed only mild stromal edema in both the staphylolysin and BSA-treated groups. CONCLUSIONS: Staphylolysin provided long-lasting protection against several strains of S. aureus, evident by both its strong anti-bacterial activity and beneficial histopathological results of treatment.